KRAS and cancer: As for malignant neoplasms, various malignant tumors were found in 60% of patients with HRAS G13R, which is notably more often than in other patient groups: in other HRAS-mut patients it was 14% (p = 0.13), in KRAS G12D patients 21% (p = 0.51), and in the whole KRAS–mut group 13 % (OR = 9.7, 95%CI = 1.9–50.6, p = 0.007), respectively.